CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity.
Xu T, Li L, Liu YC, Cao W, Chen JS, Hu S, Liu Y, Li LY, Zhou H, Meng XM, Huang C, Zhang L, Li J, Zhou H.
Xu T, et al. Among authors: hu s.
Int J Biol Sci. 2020 Jun 1;16(13):2283-2295. doi: 10.7150/ijbs.33481. eCollection 2020.
Int J Biol Sci. 2020.
PMID: 32760197
Free PMC article.
Review.